|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Importantly, ERK1/2 inhibition may have clinical utility in overcoming acquired resistance to RAF and MEK inhibitors, where RAS/MAPK pathway reactivation has occurred, such as relapsed BRAF V600E/K melanoma.
|
31710489 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF inhibitors (BRAFi) have been applied to treat melanoma harboring V600E mutations.
|
30829029 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of melanoma patients has driven the development of highly potent small inhibitors (BRAFi) of the mutated protein.
|
31401373 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here we discuss the role of ERK signaling in cell fate, in driving melanoma, and in resistance mechanisms to current BRAF-V600E melanoma treatments.
|
31190430 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Patients with BRAF V600E-mutated melanoma respond to FDA-approved BRAF inhibitors.
|
29271794 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The data reveal a very close link between the two methods, supporting the use of the V600E as a primary screen for BRAF mutations in malignant melanoma.
|
30870099 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Only one case of urethral melanoma showed a BRAF non-V600E mutation (D594G).
|
31567539 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
|
31223037 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Orthogonal partial least squares (O-PLS) predicted vemurafenib sensitivity with greater accuracy in both melanoma and non-melanoma BRAF-V600E cell lines than other leading machine learning methods, specifically Random Forests, Support Vector Regression (linear and quadratic kernels) and LASSO-penalized regression.
|
31672130 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here we assessed the role of urokinase type plasminogen activator receptor (uPAR) as a potentially valuable biomarker in the acquisition of BRAF-I resistance in V600E mutant melanoma cells.
|
30611716 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, we tested the BETi, PLX51107, for immune-based effects on tumor growth in BRAF V600E melanoma syngeneic models.
|
31063649 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The presence of a BRAF V600E mutation and activation of ERK, MEK, S6, and AKT were assessed with immunohistochemistry in 35 conjunctival nevi and 31 melanomas.
|
31247083 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The most prevalent BRAF mutation, V600E, occurs frequently in melanoma and other cancers.
|
31152574 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Specific mutations of RAF kinases, such as the prevalent BRAF(V600E) mutation in melanoma, or defects in upstream signaling or feedback loops cause decoupled kinase activities which lead to tumorigenesis.
|
28466200 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
AHR activation induces the expression of resistance genes against the inhibitors of V600E mutated B-Raf proto-oncogene, serine/threonine kinase (BRAF) in melanoma and upregulation of programmed cell death protein 1 (PD-1) in tumor-infiltrating T cells surrounding melanoma.
|
31552251 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Here, we present a case of pulmonary melanocytic nevus, involving a BRAF gene mutation (V600E), and we discuss the potential significance of this condition as a precursor to pulmonary malignant melanoma.
|
31556191 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Correlative preclinical studies demonstrated broad activity for E6201 across BRAF V600E mutant melanoma cell lines and effective BBB penetration in vivo.
|
30264293 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma.
|
30651601 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Accordingly, we evaluated the phenotypical and molecular changes of isogeneic human V600E BRAF-mutant melanoma cell line pairs pre- and post-treatment with vemurafenib.
|
31514305 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma.
|
30429474 |
2018 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study evaluated the safety and tolerability, pharmacokinetics (PK) and preliminary efficacy of dabrafenib 150 mg b.i.d. plus trametinib 2 mg q.d. in Japanese patients with BRAF V600E/K mutant solid tumors (phase 1) and melanoma (phase 2).
|
29399853 |
2018 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma.
|
30008844 |
2018 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
K63-linked ubiquitination occurs in other kinases at sites homologous to K147 in IKKβ, including K578 in BRAF V600E, which serves as an oncogenic driver in melanoma and other cancers.
|
30335863 |
2018 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A subset of melanomas carrying a B-Raf proto-oncogene, serine/threonine kinase gene (BRAF) V600E mutation, which is the most common targetable mutation in melanoma, arise in association with a melanocytic nevus that is also harboring a BRAF V600E mutation.
|
29653212 |
2018 |